HomeInsightsPE

Jagsonpal Pharmaceuticals Ltd PE Ratio

Jagsonpal Pharmaceuticals Ltd PE Ratio

stocks purchased

₹ 1.6 Cr

Volume Transacted

(Nov 22, 2024)

stocks purchased

25.6 K

Stocks Traded

(Nov 22, 2024)

Last Updated on: Nov 23, 2024

Image

Jagsonpal Pharmaceuticals Ltd

NSE: JAGSNPHARM

PE

63.5

Last updated on: Nov 23, 2024

Key Highlights

  • The P/E Ratio of Jagsonpal Pharmaceuticals Ltd is 63.5 as of 23 Nov 10:39 AM .
  • The P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 9.6 on March 2019 to 32.9 on March 2024 . This represents a CAGR of 22.79% over 6 years.
  • The Latest Trading Price of Jagsonpal Pharmaceuticals Ltd is ₹ 640.2 as of 22 Nov 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.7. The PE Ratio of Textiles industry is 37.6 in 2024.

Historical P/E Ratio of Jagsonpal Pharmaceuticals Ltd

No data available

Company Fundamentals for Jagsonpal Pharmaceuticals Ltd

No data available

Image

Jagsonpal Pharmaceuticals Ltd

NSE: JAGSNPHARM

Share Price

₹ 640.2

48.55 (8.21%)

stock direction

Last updated on: Nov 22, 2024

Market Price of Jagsonpal Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Jagsonpal Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
22 Nov 2024640.2
21 Nov 2024591.65
19 Nov 2024578.1
18 Nov 2024591.7
14 Nov 2024533.2
13 Nov 2024531.9
12 Nov 2024561.25
11 Nov 2024570.15
08 Nov 2024590.8
07 Nov 2024598.75

SWOT Analysis Of Jagsonpal Pharmaceuticals Ltd

Strength

2

S

Weakness

0

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Jagsonpal Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Jagsonpal Pharmaceuticals Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Key Valuation Metric of Jagsonpal Pharmaceuticals Ltd

No data available

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Jagsonpal Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Revenue of Jagsonpal Pharmaceuticals Ltd

No data available

* All values are in crore

Historical EBITDA of Jagsonpal Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Jagsonpal Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Dividend Payout of Jagsonpal Pharmaceuticals Ltd

No data available

* All values are in %

About Jagsonpal Pharmaceuticals Ltd

  • Promoted by J S Kochhar in 1978, Jagsonpal Pharmaceuticals is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
  • The company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
  • Simultaneously it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
  • It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
  • In 1994, the company has also promoted Aresco Financial Services, a new financial company.

Jagsonpal Pharmaceuticals Ltd News Hub

News

Jagsonpal Pharmaceuticals AGM scheduled

Jagsonpal Pharmaceuticals announced that the 45th Annual General Meeting (AGM) of the comp...

Read more

2024-08-13 00:00:00

News

Jagsonpal Pharmaceuticals standalone net profit declines 28.74% in the June 2024 quarter

Net profit of Jagsonpal Pharmaceuticals declined 28.74% to Rs 5.33 crore in the quarter en...

Read more

2024-08-08 00:00:00

News

Jagsonpal Pharmaceuticals declare Quarterly Result

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on ...

Read more

2024-08-01 00:00:00

News

Jagsonpal Pharmaceuticals to table results

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on ...

Read more

2024-10-17 00:00:00

News

Jagsonpal Pharmaceuticals standalone net profit rises 53.41% in the September 2024 quarter

Net profit of Jagsonpal Pharmaceuticals rose 53.41% to Rs 11.46 crore in the quarter ended...

Read more

2024-10-24 00:00:00

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Jagsonpal Pharmaceuticals Ltd

What is the current PE Ratio of Jagsonpal Pharmaceuticals Ltd?

The Current PE Ratio of Jagsonpal Pharmaceuticals Ltd is 63.45 as on 23 Nov 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 23 Nov 2024.

What was the PE Ratio of Jagsonpal Pharmaceuticals Ltd last year?

The PE Ratio of Jagsonpal Pharmaceuticals Ltd was 28.42 last year, now the PE ratio is 63.45, showing a year-on-year growth of 123.3%.

What does the PE Ratio of Jagsonpal Pharmaceuticals Ltd indicate about its stock?

The PE Ratio of Jagsonpal Pharmaceuticals Ltd is 63.45. This ratio indicates that investors are willing to pay 63.45 times the earnings per share for each share of Jagsonpal Pharmaceuticals Ltd.

What is the PE Ratio Growth of Jagsonpal Pharmaceuticals Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Jagsonpal Pharmaceuticals Ltd grew by 123.3% whereas, the EPS ratio grew by 121.1.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*